Baylor Research Institute

Baylor Research Institute, a nonprofit hospital and research organization headquartered in Dallas, Texas, acts as a prime recipient on federal research grants and, less frequently, as a contract prime and subcontractor. The organization operates across clinical research, health services research, and rehabilitation outcomes studies, competing in full-and-open federal grant and contract pools without SBA set-aside designations.

Baylor Research Institute's federal footprint is dominated by National Institutes of Health grants. The top five funding agencies by award count — the Department of Health and Human Services National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Diseases, the Administration for Community Living (ACL), the National Institute on Aging, and the Agency for Healthcare Research and Quality — account for 51 percent of recent awards. NIH and its subdivisions anchor the portfolio: NIH broadly has issued 24 awards, NIDDK 18 awards, and NIA 13 awards. Baylor's single contract prime award of material size is a $1.499 million firm fixed price definitive contract from CDC for vaccine effectiveness assessment during the 2021–2022 season. Representative grant work includes a $306,441 NIDDK project grant (CFDA 93.847) for a pilot randomized clinical trial of rapid, simultaneous therapy initiation in concurrent chronic kidney disease and type 2 diabetes (RAPID-CKD), running April 2026 through March 2029; a $250,000 NIDILRR (CFDA 93.433) project grant for scale-up evaluation of a diabetes prevention program adapted for traumatic brain injury (GLB-TBI), awarded September 2025 through August 2028; a $2.763 million Defense Health Agency (CFDA 12.420) project grant for a randomized controlled trial of brief prolonged exposure therapy for PTSD prevention in trauma patients, running September 2023 through September 2027; and ongoing work on the North Texas Traumatic Brain Injury Model System and Baylor Scott and White Spinal Cord Injury Model System under NIDILRR cooperative agreements and project grants extending through 2026–2027.

Activity has grown substantially: five awards in 2022 to 27 in 2024, with a modest pullback to 24 in 2025 and seven awards recorded by mid-2026. Ten awards face ultimate completion inside the next twenty-four months and therefore enter recompete windows. Baylor operates as a prime on 58 percent of recent awards and as a subcontractor on 42 percent. Sub-award work is predominantly grant-funded research where Baylor serves as a site investigator or clinical research partner under prime recipients including the University of Pennsylvania, University of Texas Southwestern Medical Center, Northwestern University, Duke University, Baylor College of Medicine, and others. The organization delivers clinical trial management, site-level data collection, patient recruitment, and regulatory coordination across multi-institutional NIH research networks.

Capability portfolio centers on clinical research execution and implementation science. Recent work spans vaccine effectiveness surveillance, diabetes prevention interventions adapted for populations with acquired brain injury (traumatic brain injury, stroke), traumatic brain injury outcomes and rehabilitation research, spinal cord injury model systems, post-intensive care syndrome characterization, cancer biomarker stratification (Barrett's esophagus carcinoma risk), mental health service delivery optimization (opioid use disorder, agitation in Alzheimer's disease, depression care), neuroblastoma treatment resistance pathways, liver transplant outcomes, and occupational health interventions for first responders. Work is performed at Baylor Scott & White clinical sites across Texas — Dallas, Temple, Round Rock, and Fort Worth locations — with administrative oversight at the Dallas headquarters.

The SCI dataset (covering service contracts above $150,000 from FY2022–FY2024) shows sparse reportable prime activity: $278 thousand in invoiced revenue in FY2022 with 5.0 FTEs, stepping down to 5.5 FTEs by FY2024. Government-paid hourly rates on prime SCI contracts ran median $26.32 per hour with a tight distribution ($25.59–$27.05 across the 10th to 90th percentile range), reflecting standard research support labor. The sub-hours share on Baylor prime contracts was zero percent, indicating the organization builds its own delivery teams rather than engaging subcontractors for execution. The SCI footprint does not capture Baylor's substantial grant revenue and multi-million-dollar cooperative agreement activity — those federal research dollars and the clinical team effort they fund are not reportable under the Service Contract Inventory threshold and reporting rules. Federal grant potential value appears artificially low in the source ($3 million combined potential value) because grants typically carry discrete, non-renewable funding amounts rather than option periods that inflate contract ceiling values.